

CASPR Impact Report

Celebrating growth, inspiring the future



The Coalition to Accelerate and Support Prevention Research (CASPR) is an Africa-led advocacy network and movement, focused on advancing biomedical HIV prevention research and equitable access to proven HIV prevention products.

CASPR, funded by the United States Agency for International Development (USAID) and supported by AVAC, was intended to run from 2016 through 2026, but was paused in early 2025 amidst sweeping cuts to US federal funding for foreign assistance and the dismantling of USAID.

This report highlights the Coalition's achievements and key wins over the course of eight years. These include significant impact on elevating community needs, expanding the field of HIV advocacy, promoting inclusive engagement in research, and improving ethical standards in HIV prevention research.



CASPR Kick-off Meeting in Nairobi, Kenya (2016)



CASPR Annual Meeting in Lusaka, Zimbabwe (2024)

Table of Contents

Looking Back: The Need for CASPR.....	1
CASPR Through the Years.....	2
The Evolution of a Global Advocacy Network.....	3-4
CASPR's Impact at a Glance.....	5-6
Shaping global standards: Influencing ethical guidelines in HIV clinical research.....	7-8
Bridging the gap between science and communities: Promoting inclusive engagement in research.....	9-10
Expanding the HIV advocacy ecosystem: Building a stronger, intergenerational advocacy movement....	11-12
Elevating community needs as a policy priority: Making choice a cornerstone of HIV Prevention Policy.	13-14
Sustaining Africa-centered HIV Prevention Advocacy.....	15

Abbreviations

AGYW: Adolescent Girls and Young Women	HVTN: HIV Vaccine Trials Network
AWPCAB: African Women's Prevention Community Accountability Board	IAS: International AIDS Society
CASPR: Coalition to Accelerate and Support Prevention Research	KP: Key Populations
COP: Country Operational Plan	MERL: Monitoring, Evaluation, Research, and Learning
CTDA: Clinical Trial Design Academy	MTN: Microbicide Trials Network
D4P: Descovy for PrEP	PEPFAR: US President's Emergency Plan for AIDS Relief
DOH: Department of Health	PLP: Pregnant and Lactating People
ECHO: Evidence for Contraceptive Options and HIV Outcomes	PRA: People's Research Agenda
EDI: Equity, Diversity, and Inclusion	PrEP: Pre-exposure Prophylaxis
FP: Family Planning	R&D: Research and Development
GCAG: Global Community Advisory Group	REC: Research Ethics Committee
GPP: Good Participatory Practice	USAID: United States Agency for International Development
HAVEG: HIV AIDS Vaccines Ethics Group	WHO: World Health Organization
HIV: Human Immunodeficiency Virus	YWHPC: Young Women's HIV Prevention Council
HPTN: HIV Prevention Trials Network	

Looking Back: The Need for CASPR

The Challenge

In 2016, the year that CASPR launched, 1.8 million new HIV infections were recorded worldwide and efforts to reach global HIV prevention targets were significantly off track.¹ While several HIV prevention options were available - including highly effective oral PrEP - they were not widely accessible, nor were they enough to meet the varied needs of diverse individuals over a dynamic lifetime. As research for new prevention technologies advanced, the challenge was clear: there was a dire need to **scale up available prevention tools while sustaining momentum for research and development (R&D)**. Both R&D and scale up were essential to slow the unacceptably high rates of new HIV infections that disproportionately affected cisgender women and key populations in Africa. With global resources for HIV shrinking, a coordinated and strategic response characterized by strong community engagement was vital for progress.

The Response

To address this challenge, AVAC, partners, and USAID conceptualized CASPR to **develop and sustain an Africa-centered advocacy network to accelerate biomedical HIV prevention research**. The Coalition aimed to change how HIV prevention is designed and delivered, and implemented a robust suite of initiatives focused on advocacy and policy engagement, research translation, and research preparedness. CASPR was initially funded by USAID as a five-year project, but was renewed for an additional five years through 2026. This allowed CASPR to expand beyond its primary focus on research to play a critical role in supporting equitable introduction and access to new HIV prevention products. Underpinning this work was a commitment to equity, diversity, and inclusion (EDI) and gender transformation, as well as strong Monitoring, Evaluation, Research, and Learning (MERL) and coordination systems.



Advocacy Network & Policy Engagement

Strengthen a global advocacy network for HIV prevention research; push for policies that facilitate efficient & ethical development, intro, & use of new HIV prevention methods



Research Translation

Translate research to ensure scientific advancements inform and support policies and practices that uphold stakeholder needs & interests



Research Preparedness

Ensure the rights and interests of trial participants, eventual users, and communities are represented and respected from research to rollout

Monitoring, Evaluation, Research & Learning (MERL) + Equity, Diversity & Inclusion + Gender Integration + Coordination

CASPR Through the Years



2016–2017: Building New Structures

Launched CASPR with 9 partners as 4 efficacy trials began; focused on coalition-building, infrastructure, and shared strategy.



2018–2019: Shaping a Community-Centered HIV Agenda


CASPR matured as a Coalition; responded to ECHO results with integrated advocacy, centered African women, and promoted domestic financing for HIV and FP.

2020–2022: Elevating GPP as Core to Research

Drove deep engagement with IMPOWER, PURPOSE, and PrEPVacc; established GCAGs, pioneered pharma partnerships, and convened 73 stakeholder consultations.

2023–2024: Championing Choice

Launched African Women's Prevention Community Accountability Board (AWPCAB) and the HIV Prevention Choice Manifesto, advancing African women's leadership and voice in shaping HIV prevention research and rollout.



2017–2018: Catalyzing Advocacy for Women's HIV Prevention

Positioned community and end-user voices at the center of new trials and policy translation; prioritized women's HIV prevention across advocacy and communications.



2019–2020: Maintaining Momentum for Vaccine Science

Led field response to HVTN 702 trial results and COVID-19; upheld vaccine advocacy, adapted GPP for new pandemics, and strengthened capacity to sustain connection in a virtual world.

2022–2023: Supporting Next-Generation Leadership

Championed youth-led advocacy and leadership; Emerging youth leaders influenced policies, secured seats at decision-making tables, and earned national recognition.




2024–2025: Bridging Research to Rollout

Focused on sustaining advocacy across trial-to-rollout; champions and Fellows influenced national policies, Country Operating Plan (COP) processes, and national dialogues on prevention access.

1. https://www.unaids.org/sites/default/files/media_asset/20170720_Data_book_2017_en.pdf

The Evolution of a Global Advocacy Network

At its inception, CASPR was comprised of nine core partners. Over time, the Coalition evolved, becoming a network that responded to and anticipated emerging needs in HIV prevention and increased the role of civil society advocates. By 2024, CASPR had expanded to **thirteen core partners** – nine Africa-based in Eastern and Southern Africa, and four international organizations. Partners brought diverse expertise to the Coalition, ranging from grassroots advocacy to science media to research engagement and ethics. From the outset, CASPR was designed to leverage and strengthen African advocacy to advance a long-term response.



CASPR built a successful, multi-country advocacy movement through **global collaboration** with an emphasis on **localized leadership**. While AVAC served as the prime and led vital grant management and coordination efforts, strategic thinking and decision-making was shared across the Coalition. CASPR partners not only set the advocacy agenda, but also visibly led in community, national, regional, and global arenas.

When CASPR was unexpectedly suspended in January 2025, the Coalition was in the process of co-creating a future partnership model that would further center African leadership through the end of the project, and beyond. **CASPR's intentional approach to co-creating an African-led transnational coalition has several lessons to offer as the global health field accelerates localization.** Partners emphasized the following as key considerations for leadership transitions:

- **Strategic Transition:** Emphasizing the need for a gradual transition of leadership to ensure minimal disruption and smooth capacity building
- **Shared Power and Decision-making:** Advocating for a power-sharing approach between the Global North and South, with mechanisms for capacity building for African partners
- **Inclusive and Participatory Governance:** Ensuring that the governance structure is inclusive, allowing all partners to have a voice in decision-making and fostering a participatory environment
- **Mentorship and Capacity Building:** Highlighting the importance of ongoing mentorship from previous leads and building strong structures that command respect at a global level

The CASPR experience makes it clear that localization is not as simple as shifting a grant agreement. In addition to co-creation and a strategic handover, CASPR demonstrates the power of centering local leadership within a **global network** for achieving greater collective outcomes.

“That’s one of the many things I take with me [from CASPR]...when you invest in leadership, even when the program or the project closes, the infrastructure remains.”
Rosemary Mburu, WACI Health

“From the start, CASPR has been an African-led initiative... all the work done is anchored by African partners.”
CASPR Partner



The Young Women's HIV Prevention Council (YWHPC) with Dr. Linda-Gail Bekker at ICASA 2023 conference

CASPR's Impact At a Glance

CASPR has created a sustainable platform to advance African-centered leadership and the crucial advocacy needed to ensure a robust pipeline of HIV prevention options reach the people who need them most.


In eight years, CASPR has:

- Advanced ethical, community-centered research design in HIV vaccine and PrEP trials, ensuring that stakeholder perspectives are incorporated into every step of the process
- Cultivated community trust in the research process, increasing access to accurate scientific information and expanding community engagement in HIV prevention research
- Built broad consensus on community priorities for the HIV prevention R&D pipeline, resulting in critical buy-in and support from researchers, funders, and decision-makers
- Championed choice in HIV prevention R&D and rollout, with a strong focus on girls and women, successfully accelerating access to products that communities need
- Secured critical commitments from product developers on access and price transparency to advance the introduction of new HIV prevention products

Through strategic partnerships, consistent mentorship, and advocacy for ethical HIV prevention research and access, CASPR has shaped how communities engage with science, built bridges of trust across different stakeholder groups, and shifted systems by influencing policy change.

Read on to learn how CASPR transformed HIV prevention research advocacy in East and Southern Africa.

Key Outcome Areas



Shaped global standards by influencing ethical guidelines in HIV clinical research



Expanded the field of HIV prevention advocacy and leadership by building a stronger, intergenerational advocacy movement




Bridged the gap between science and communities by promoting inclusive engagement in research





Elevated community needs as a policy priority, making choice a cornerstone of HIV prevention research and policy

Achievements By the Numbers



Shaping global standards: Influencing ethical guidelines in HIV clinical research

CASPR played a critical role in ensuring community priorities are reflected in research by influencing researchers, funders, and government ministries to integrate the Good Participatory Practice (GPP) guidelines in clinical trial design and conduct. The GPP guidelines were developed by AVAC in collaboration with UNAIDS and outline best practices to ensure communities are meaningfully engaged in the design, implementation, and oversight of biomedical research and clinical trials.



- By influencing policy, engaging researchers and funders, and serving on accountability mechanisms, CASPR has transformed the role of advocates and ensured increased prioritization of inclusive, ethical, and community-centered research. CASPR worked to institutionalize the guidelines in a number of ways, including:
- AVAC provided recommendations that were included in WHO’s recently updated guidelines for clinical trials (2024) emphasizing the importance of patient, participant, and community engagement; embedding GPP principles into global research standards.
 - In South Africa, HAVEG’s strategic submissions to the Department of Health (DOH) resulted in the inclusion of recommendations for strengthening stakeholder engagement practices through the Research Ethics Committee (REC) review process in the national ethics guidelines (DOH 2024). The updated guidelines now emphasize the need for adaptive engagement strategies and contextual responsiveness.
 - GPP was embedded in the new WHO Global Clinical Trials Forum (2025), a network aimed at strengthening the clinical trial environment and infrastructure.

CASPR leadership on clinical trial accountability mechanisms ensured the prioritization of trial designs that are ethical, transparent, and community-centered. A few examples include:



REACH (MTN 034) consultation, Zimbabwe


In MTN-034 and MTN-042 (the Dapivirine Ring trials), CASPR-led consultations informed trial design that resonated with adolescent girls and young women, contributing to broader community support and uptake. A number of recommendations from the consultations were incorporated into the study protocol, for example, researchers agreed to follow infants born during or after the study for a longer period, and to find ways to establish a better baseline for adverse and healthy outcomes in pregnancy in the relevant communities.



ECHO forum, Nairobi

As results were released from the ECHO trial (assessing whether the risk of acquiring HIV differed among three different contraceptive methods), CASPR ensured African women were meaningfully engaged in disseminating and interpreting results, helping to shape an ethical, community-centered response. CASPR's rallying cry for "women at the center" in the wake of ECHO later shaped Gilead's trial design and engagement strategy as they planned their first HIV prevention efficacy trial in women in Africa - D4P, studying F/TAF for PrEP in cisgender women.

When HPTN 083 showed that injectable CAB is safe and effective in cisgender men and transgender women, CASPR led discussions to translate the results and pushed for continued investigation of CAB in cisgender women via the ongoing HPTN 084 trial. CASPR advocated for comprehensive regulatory planning for and established critical engagement mechanisms to ensure no population would be left behind.



CASPR partners influence PURPOSE 1 trials as members of the GCAG

CASPR partners played a pivotal role in ensuring the PURPOSE trials (studying Lenacapavir for PrEP) adhered to GPP principles from trial design to results dissemination. CASPR chaired the PURPOSE 1 global community advisory group (GCAG), held six of its eight seats, and ensured young women were included on the GCAG and in the research, from the start. The GCAG also secured protocol changes allowing pregnant and breastfeeding individuals to remain in the trial after re-consent, and the Civil Society Caucus for Long-Acting PrEP pushed Gilead to publicly announce a commitment to ensuring equitable access. By embedding GPP throughout the process, CASPR ensured that the trials for lenacapavir were conducted ethically and included communities, setting a standard for future clinical research.

Bridging the gap between science and communities: Promoting inclusive engagement in research

CASPR built bridges between communities and researchers, creating space for communities to be informed and meaningfully consulted throughout the research process and ensuring that science is accessible, inclusive, and responsive to community needs. CASPR supported mechanisms that encouraged community-led engagement in clinical trial consultative groups, more accurate and credible journalism on prevention science, and strengthened relationships between advocates and the scientific community.

“Thanks to the Trial Design Academy’s ongoing capacity-building sessions—I can confidently speak about how HIV prevention clinical trials have evolved—and why it’s so important to center community needs and preferences in next-gen trial designs”



Clinical Trial Design Academy, 2024 cohort

The Clinical Trial Design Academy (CTDA) is a CASPR initiative that seeks to strengthen research literacy skills of civil society partners and advocates. A cohort of 20 African-based advocates were trained to partner with researchers, industry, and regulators as they determine how to make critical decisions on the design and conduct of next-generation HIV prevention trials. CTDA members have been selected to participate in global community advisory groups for biomedical HIV prevention trials and for ethics review boards.

The People’s Research Agenda (PRA) provides recommendations to diversify and strengthen the HIV prevention pipeline, sustain investment for prevention R&D, and guide an advocacy strategy addressing the needs of communities across the prevention pipeline. The document was developed through a consultative process with 138 actors across 23 countries to gain input about the process and products needed to realize prevention justice. The PRA ensures the voices of those most affected by HIV are heard and integrated into HIV prevention R&D.



PRA launch at R4P, 2024; Jeanne Marrazzo publicly endorses document

The Media Science Café program equipped hundreds of local journalists with the knowledge and tools to accurately report on HIV prevention and vaccine research and the rollout of new products. Cafés were convened by journalist organizations in Kenya, Malawi, Uganda, Tanzania, Zambia, Zimbabwe - bringing together journalists, scientists, and advocates for informal discussions where they collectively engaged, gaining clarity on complex biomedical research. The program has forged critical cross-sector relationships and facilitated accurate journalism, ultimately leading to community trust of science and R&D.



Dr. Flavia Matovu, Director of Research at Makerere University, reflects on a media orientation on Purpose 1 trial results hosted by Uganda’s MOH and HEJNU.



Despite challenging results from a series of vaccine trials – Imbokodo, Mosaico, PrEPVacc, Uhambo – CASPR partners successfully led efforts to translate results for the public, championed research literacy and community engagement in next-generation vaccine discovery trials, and ensured lessons learned inform future vaccine trial design. Journalists in the Media Science Café network played a critical role, ensuring robust coverage of complicated results. This rapid response in the wake of trial results positioned the Coalition as a go-to research translation partner for researchers and communities alike.

“Evidence-based information really wins, and that’s what we do with the cafés”
Esther Nakkazi, HEJNU



A MESHA Café in Western Kenya with community members

HIV VACCINE: Experts Call for Continued Research after Disappointing Trial – TowerPostNews
On Tuesday 31st August 2021, Johnson & Johnson and partners thetowerpost.com



Media Science Café conveners organized a call with 45 journalists within 3 hours of the announcement that Imbokodo (HVTN 705) was stopped early for non-efficacy. Regional in-person cafés followed (above).

Expanding the field of HIV prevention advocacy and leadership: Building a stronger, intergenerational advocacy movement

CASPR nurtured advocates and strengthened intergenerational advocacy by building a robust pipeline of new advocates for a more sustainable HIV prevention advocacy movement that influences research, policy, and implementation. Since 2016, CASPR expanded from two to eight mentorship programs across seven partner organizations, reaching over 700 emerging advocates in 15 countries. This includes the *AfNHI Youth Cohort*, *APHA's Ground Forces*, *AVAC's Advocacy Fellows Program*, *PZ HIV Prevention Champions*, *TALC Ascend Mentorship Youth*, and the *Young Women's HIV Prevention Council*, among others. Alumni of CASPR mentorship programs described the programs as "transformative", expressing increased confidence, skills, and readiness to lead and reciprocate mentorship to newer advocates. Through mentorship programs, coalition-building, and strengthening research literacy, CASPR supported youth leadership to drive change at national, regional, and global levels. Mentees have been invited to share priorities and perspectives during sessions at global conferences, as part of national technical working groups, and in preparation for clinical trials.




TALC Ascend Mentorship Youth



2024 APHA Ground Forces



AfNHI Youth Cohort Mentees



2024-2025 AVAC Advocacy Fellows Cohort

The *AVAC Advocacy Fellowship program*, supported by CASPR, equipped young advocates with skills for evidence-based policy engagement and research literacy. Over 15 years, the program supported almost 100 advocates across 15 countries to carry out advocacy projects aimed at improving the HIV response in their communities. Collectively, AVAC Fellows have driven widespread impact, founding or leading 85+ influential organizations and campaigns and serving on 150 high-level decision-making bodies to influence global and national health agendas.



First LeNNiB Champions Cohort (2017)



Members of YWHPC at ICASA



PZ HIV Prevention Champions

CASPR's work to expand the HIV advocacy ecosystem and diversify the community voices shaping research and policy is a key legacy of the Coalition's work that lives on.

CASPR facilitated the NHVMAS youth mentorship programme - LeNNiB Champions - an initiative that has continued to run beyond CASPR support

Florita Dureke, Executive Director, NHVMAS

AGYW leadership: CASPR prioritized AGYW voices by launching leadership programs and supporting opportunities for peer-to-peer knowledge and skills sharing, and direct engagement with high-level stakeholders. CASPR trained nearly 400 AGYW in community-level advocacy through these initiatives.

CASPR's *Young Women's HIV Prevention Council (YWHPC)* (founded in 2023) amplifies AGYW perspectives in prevention policy and research, ensuring strategies reflect their lived experiences. Members of the YWHPC sit on research advisory committees as youth representatives and leverage social media to translate prevention information into digestible pieces of information for their peers. The far-reaching impact of the CASPR model is reflected in the ongoing capacity of these youth leaders, who have continued to advocate effectively for youth-centered HIV policies after CASPR funding was eliminated.



Young women taking notes during the HIV Prevention Symposium, Zimbabwe



2017 AVAC Advocacy Fellows

Elevating community needs: Making choice a cornerstone of HIV prevention research and policy


CASPR has shifted the global narrative on HIV prevention by centering choice - the ability to access a range of HIV prevention options that meet diverse and evolving needs - as core to achieving equity in the HIV response. Choice is critical from the conceptualization of HIV prevention research to the implementation of proven HIV prevention products. CASPR partnered with affected communities, especially AGYW and key populations, to develop tools, create engagement mechanisms, and implement evidence-based advocacy campaigns around choice. The Transgender Manifesto, KP Roadmap, PLP Action Plan, and Choice Manifesto are examples of CASPR initiatives that helped shape HIV prevention research and policy agendas.



The Transgender Manifesto "No Data No More" provides a vision for a relevant and inclusive trans and gender-diverse research agenda, with recommendations to fulfill an inclusive future for HIV research. The Manifesto has guided over 15 multi-stakeholder dialogues; its trans-inclusivity scorecard offers a framework for designing inclusive research.



The Global HIV Prevention Roadmap for Key Populations outlines a KP-led strategy for the equitable expansion and delivery of HIV prevention services to KPs globally and regionally. The roadmap was a starting point for KP groups to forecast global demand for PrEP.




The Choice Manifesto advocates for choice in HIV prevention options available for women and a commitment to an HIV prevention research agenda that is shaped by women and girls. The Manifesto garnered high-level support and transformed field-wide discourse on the importance of choice in the HIV response.



The Action Plan for Advancing HIV Prevention Research in PLP outlines four priority actions and concrete steps for advancing ethical, responsible HIV prevention research in PLP. It has brought awareness to the pivotal role of collaboration in sustaining momentum for PLP research inclusion.

The African Women's Prevention Community Accountability Board (AWPCAB) was established by CASPR partners as a network led by and for African women, advocating for sustained financial and political commitment to HIV prevention choice. The AWPCAB launched the Choice Manifesto in 2023, securing commitments and sign-ons from high-level stakeholders such as Winnie Byanyima, Executive Director of UNAIDS, representatives from USAID, and African ministries of health.



The Choice Manifesto is an important and timely advocacy tool. It will help advocates lobby for resources and political will towards making HIV prevention options available for women and girls in Africa

Grace Kumwenda, AVAC

Top: Members of the AWPCAB pose with Winnie Byanyima at the Choice Manifesto Launch, Uganda 2023
Bottom Left: A social media post by Winnie Byanyima on the launch
Bottom right: Signed commitments from attendees at the launch

Beyond the Choice Manifesto, the AWPCAB has been a consistent voice for community priorities. When PURPOSE 1 trial results were released, they were among the first to rapidly respond, demanding equitable roll-out and access, and issuing a public call to action that was further amplified in a NY Times article. Additionally, following the drastic funding cuts in early 2025, they called on global health institutions, African governments, donor countries, the private sector, and philanthropies

to urgently address critical gaps to ensure a sustainable HIV response. The AWPCAB's leadership in policy advocacy ensures community priorities continue to shape the broader HIV policy agenda. HIV prevention is not one-size-fits-all; it requires context-specific approaches and solutions centered on community priorities. By centering the voices of women, youth, and key populations, CASPR not only influenced agendas for research and access, but also promoted the principle that inclusive, person-centered options are essential for an effective HIV response.

Sustaining Africa-Centered HIV Prevention Advocacy

The advocacy movement created by CASPR continues to have impact, and CASPR partnerships remain strong. The leadership of CASPR partners was clear at the International AIDS Conference (IAS) in Kigali in July 2025. CASPR partners were front and center, demanding equity, human rights, and community leadership as the field grappled with how to move forward amidst detrimental attacks to global health. WACI Health’s Rosemary Mburu captured this call to action at the opening session, saying:



Rosemary Mburu speaks on sustaining community action at the opening session of IAS 2025

“Community action is not the soft side of science — it’s what gives science its soul, its reach, and its relevance.”



CASPR partners led at IAS 2025 from the main stage, in satellite sessions, at a networking booth, and more

CASPR set a precedent as a leading voice and presence at major HIV conferences throughout the project's duration. By 2025, It was rare to attend a session that was not convened by CASPR or featured partners as speakers. CASPR partners dominated hallway conversations, especially at the Coalition’s networking zone where researchers, advocates, and policymakers came together to discuss the latest issues.

While CASPR leadership was on display in Kigali through individual partners, sustaining the collective force of CASPR will require new investments by donors committed to Africa-centered advocacy. CASPR has built the necessary infrastructure, expertise, and trust for transforming the landscape of HIV, and demonstrated the need for such a collective moving forward. Now is the time to re-invest to safeguard the future of progress in HIV prevention.



CASPR has undoubtedly shaped the prevention landscape, in Africa and globally. By fighting for the advancement of community-centric research agendas, and for research to move to rollout as efficiently and equitably as possible, this global network of advocates has helped evolve and improve prevention options and realities for their communities, countries, and the world.

Stacey Hannah, CASPR Director, AVAC

HIV prevention is at a crossroads. On the one hand, an array of effective HIV prevention products now exists, thanks to a robust R&D pipeline and strong advocacy. But on the other hand, attacks on health and human rights and dramatic cuts to PEPFAR and US foreign aid imperil progress and the sustainability of the HIV response. These funding and programmatic cuts have already had detrimental consequences on human health. Strong advocacy is needed to maintain support for HIV prevention research and introduce new products with speed, scale, and equity.

CASPR's Key Lessons for Global Coalition Building

- **Working collectively towards desired outcomes** for HIV prevention research built cohesion and purpose among the Coalition
- **A long history and strong relationships** facilitated effectiveness and cohesiveness
- **Diversity in Coalition expertise** created a unique learning environment
- **Documenting achievements and sharing successes** with the right people at the right time was critical to Coalition visibility
- **Intentionally uplifting young and female voices** created platforms for them to lead and invests in the next generation of advocates

The field must invest in global networks like CASPR, and the platforms they’ve built, to continue progress in the fight against HIV.



For more information, visit <https://avac.org/project/caspr/> and <https://avac.org/>.